Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
{{familytree | | | | | | | | | | | |!| | | | | | | | | }} | {{familytree | | | | | | | | | | | |!| | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}} | {{familytree | | | | | | | | | | | C01 | | | | | | |C01=Histopathologic examination}} | ||
{{familytree | | | | | |, | {{familytree | | | | | |,|-|-|-|-|-|+|-|-|-|-|-|.| | | }} | ||
{{familytree | | | | |D01 | {{familytree | | | | |D01| | | | D02| | | | D03 |D01='''Squamous cell carcinoma'''|D02='''Neuroendocrine carcinoma'''|D03='''Adenocarcinoma and poorly differntiated carcinoma'''}} | ||
{{familytree | | | | | |! | {{familytree | | | | | |!| | | | | |!| | | | | |!| | | | }} | ||
{{familytree | | | | | |! | {{familytree | | | | | |!| | | | |boxstyle=text-align: left;|E01| | | | |!| |E01=• Octreoscan<br> • Plasma chromogranin A}} | ||
{{familytree | | | | |F01 | {{familytree | | | | |F01| | | | | | | | | | F02 | |F01=Additional tests specific to location of metastasis|F02=Gender specific tests}} | ||
{{familytree | | | | | |!| | | | | | | | | | | | | | {{familytree | | | | | |!| | | | | | | | | | | |!|| | }} | ||
{{familytree | | |,|-|-|+|-|-|-|. | {{familytree | | |,|-|-|+|-|-|-|.| | | | | |,|-|^|-|.| | | }} | ||
{{familytree | G01 | | G02 | | G03 | {{familytree | G01 | | G02 | | G03 | | | | G04 | | G05 | | | |G01=Cervical adenopathy|G02=Inguinal adenopathy|G03=Bone metastasis|G04=Male|G05=Female}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 20:36, 10 October 2018
| Tumor of unknown primary origin | |||||||||||||||||||||||||||||||||||||||||||||||
| • Full medical history and physical exam • Basic blood and bichemical analysis • CT scan of chest, abdomen, and pelvis | |||||||||||||||||||||||||||||||||||||||||||||||
| Histopathologic examination | |||||||||||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | Neuroendocrine carcinoma | Adenocarcinoma and poorly differntiated carcinoma | |||||||||||||||||||||||||||||||||||||||||||||
| • Octreoscan • Plasma chromogranin A | |||||||||||||||||||||||||||||||||||||||||||||||
| Additional tests specific to location of metastasis | Gender specific tests | ||||||||||||||||||||||||||||||||||||||||||||||
| Cervical adenopathy | Inguinal adenopathy | Bone metastasis | Male | Female | |||||||||||||||||||||||||||||||||||||||||||